drugset / Trial / NCT02780180

QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF

NCT02780180

Phase 2 Terminated 23 enrolled Quantum Genomics SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction. A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway, may lead to improve HF. QCG001 is a prodrug of EC33, a aminopeptidase A (APA) inhibitor. QCG001 has been shown to be an antihypertensive agent in animal models. This study investigates the safety and efficacy of QGC001 in HF patients.

Timeline

Start
2016-06
Primary completion
2018-09-12
Completion
2018-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Firibastat Small molecule 500 mg Oral

Indications